PMID- 35116772
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220501
IS  - 2219-6803 (Electronic)
IS  - 2218-676X (Print)
IS  - 2218-676X (Linking)
VI  - 8
IP  - 2
DP  - 2019 Apr
TI  - A mechanism of regucalcin knock-down in the promotion of proliferation and 
      movement of human cervical cancer HeLa cells.
PG  - 402-409
LID - 10.21037/tcr.2019.02.01 [doi]
AB  - BACKGROUND: Regucalcin (RGN) has been reported to have inhibitory effects on the 
      proliferation and migration of many cancer cells. In this research, RGN 
      expression has been silenced to study its effects on human cervical cancer HeLa 
      cells. METHODS: Lentivirus mediated siRNA was infected into HeLa cells by 
      lentivirus vector. The RGN expression was measured by quantitative real-time PCR 
      (RT-qPCR) and Western blotting (WB). Cell count kit-8, colony formation assay and 
      transwell assay were used to detect cell proliferation, migration and invasion. 
      The expression of Wnt/beta-catenin pathway and epithelial-mesenchymal transition 
      (EMT) related proteins, including beta-catenin, GSK-3beta, p-GSK-3beta, matrix 
      metalloproteinase-3 (MMP-3), matrix metalloproteinase-7 (MMP-7), matrix 
      metalloproteinase-9 (MMP-9), E-cadherin, N-cadherin and vimentin, were detected 
      by WB. RESULTS: Compared with HeLa-NC cell line, the expressions of RGN and 
      E-cadherin in HeLa-siRGN cell lines are significantly decreased, while the 
      expressions of beta-catenin, MMP-3, MMP-7, MMP-9, p-GSK-3beta, N-cadherin and vimentin 
      increased. The RGN down-regulation has been observed to promote cell 
      proliferation, enhanced cell migration and invasion. CONCLUSIONS: The 
      down-regulation of RGN may enhance the activity of metastasis related signaling 
      pathway Wnt/beta-catenin and EMT in the progression of cervical cancer.
CI  - 2019 Translational Cancer Research. All rights reserved.
FAU - Li, Xiaolong
AU  - Li X
AD  - Department of Cell Biology and Genetics, School of Pre-Clinical Medicine, Guangxi 
      Medical University, Nanning 530021, China.
AD  - Department of Biochemistry and Molecular Biology, School of Pre-Clinical 
      Medicine, Guangxi Medical University, Nanning 530021, China.
FAU - Huang, Yingwen
AU  - Huang Y
AD  - The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning 
      530023, China.
FAU - Wang, Pengfei
AU  - Wang P
AD  - Department of Biochemistry and Molecular Biology, School of Pre-Clinical 
      Medicine, Guangxi Medical University, Nanning 530021, China.
FAU - Song, Wei
AU  - Song W
AD  - Department of Biochemistry and Molecular Biology, School of Pre-Clinical 
      Medicine, Guangxi Medical University, Nanning 530021, China.
FAU - Yao, Qingmei
AU  - Yao Q
AD  - Department of Biochemistry and Molecular Biology, School of Pre-Clinical 
      Medicine, Guangxi Medical University, Nanning 530021, China.
FAU - Hu, Qiping
AU  - Hu Q
AD  - Department of Cell Biology and Genetics, School of Pre-Clinical Medicine, Guangxi 
      Medical University, Nanning 530021, China.
FAU - Zhou, Sufang
AU  - Zhou S
AD  - Department of Biochemistry and Molecular Biology, School of Pre-Clinical 
      Medicine, Guangxi Medical University, Nanning 530021, China.
AD  - National Center for International Research of Biological Targeting Diagnosis and 
      Therapy, Guangxi Key Laboratory of Biological Targeting Diagnosis and Therapy 
      Research, Collaborative Innovation Center for Targeting Tumor Diagnosis and 
      Therapy, Guangxi Medical University, Nanning 530021, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Transl Cancer Res
JT  - Translational cancer research
JID - 101585958
PMC - PMC8797288
OTO - NOTNLM
OT  - HeLa
OT  - Regucalcin (RGN)
OT  - invasion
OT  - migration
OT  - proliferation
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at http://dx.doi.org/10.21037/tcr.2019.02.01). The authors have 
      no conflicts of interest to declare.
EDAT- 2019/04/01 00:00
MHDA- 2019/04/01 00:01
PMCR- 2019/04/01
CRDT- 2022/02/04 05:49
PHST- 2018/10/17 00:00 [received]
PHST- 2019/01/23 00:00 [accepted]
PHST- 2022/02/04 05:49 [entrez]
PHST- 2019/04/01 00:00 [pubmed]
PHST- 2019/04/01 00:01 [medline]
PHST- 2019/04/01 00:00 [pmc-release]
AID - tcr-08-02-402 [pii]
AID - 10.21037/tcr.2019.02.01 [doi]
PST - ppublish
SO  - Transl Cancer Res. 2019 Apr;8(2):402-409. doi: 10.21037/tcr.2019.02.01.